MedTrace Logo

Acetylcarnitine and Metabolic Flexibility

NCT02072759 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-07-14

No results posted yet for this study

Summary

Insulin resistant subjects and type 2 diabetic patients are characterized by a decreased metabolic flexibility: a reduced capability to switch from fat oxidation in the basal state to carbohydrate oxidation in the insulin-stimulated state. This metabolic inflexibility is an early hallmark in the development of diabetes. Recent evidence suggests that a low carnitine availability may limit acetylcarnitine formation, thereby reducing metabolic flexibility. We propose to test the hypothesis that metabolic inflexibility in pre-diabetic subjects and diabetic patients is due to a reduced capacity to form acetylcarnitines.

Conditions

  • Glucose Intolerance

Interventions

DIETARY_SUPPLEMENT

Carnitine supplement

Carnitine supplement (oral ingestion with meals) Total dosage of 2g carnitine per day for 36 days. * 1 carnitine supplement at breakfast (500mg) * 1 carnitine supplement at lunch (500mg) * 2 carnitine supplements at diner (2x 500mg=1000mg)

DIETARY_SUPPLEMENT

Placebo

Sponsors & Collaborators

  • European Foundation for the Study of Diabetes

    collaborator OTHER

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • Vera B Schrauwen, PhD · Maastricht University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02072759 on ClinicalTrials.gov